Therapeutics News and Research

RSS

Acorda Therapeutics receives U.S. patent allowance for aminopyridine compositions

Acorda Therapeutics, Inc. today announced that the United States Patent and Trademark Office (USPTO) has allowed U.S. Patent Application No. 11/102,559 entitled "Method of Using Sustained Release Aminopyridine Compositions."

10 Aug 2011

BIDMC researchers receive PCF Challenge Awards for novel prostate cancer study

Beth Israel Deaconess Medical Center (BIDMC) researchers Martin Sanda, MD, and Steven Balk MD, PhD, have been awarded Challenge Awards of $1 million each from the Prostate Cancer Foundation (PCF) to lead two cross-disciplinary teams of investigators in their pursuit of new treatments for patients with advanced prostate cancer.

10 Aug 2011

Enobia raises US$40M through private placement

Enobia Pharma Inc., a clinical stage biotech company focused on developing novel therapeutics for serious bone disorders, today announced that it has raised US$40 million through the private placement of approximately 13,724,000 shares of its common stock to new pharmaceutical and financial investors.

10 Aug 2011

Akela announces new corporate focus on PharmaForm

Akela Pharma, Inc. today announced a new strategic focus on its profitable pharmaceutical contract manufacturing business, PharmaForm, LLC.

9 Aug 2011

InVivo announces Platinum sponsorship to W2W spinal cord injury symposium

InVivo Therapeutics today announced the Company's Platinum level sponsorship of the 6th annual Working 2 Walk Science and Advocacy Symposium, which will take place October 16-18, 2011 in Rockville, Maryland.

9 Aug 2011

Nottingham researchers to develop new early warning system for Alzheimer's

Researchers at The University of Nottingham have been awarded £670,000 to develop a new early warning system for Alzheimer's disease.

9 Aug 2011

New preclinical approach can guide more efficient drug development for brain-related conditions

The development of drugs for brain-related conditions is not an efficient process; only 8% of candidate drugs that enter clinical trials gain FDA approval. A key reason for this low success rate is a lack of preclinical tests that accurately predict drug efficacy and detect unwanted side effects.

9 Aug 2011

EPO issues European patent for Rexahn's neurotherapeutic compositions

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office (EPO) has granted European patent No. EP1212055 entitled "Neurotherapeutic compositions comprising a beta-lactam compound."

9 Aug 2011

Kaan Medikal to distribute Saladax's My5-FU diagnostic test in Turkey

Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Kaan Medikal will serve as the exclusive distributor of Saladax's My5-FU diagnostic test throughout the Turkish market.

8 Aug 2011

Unigene second quarter revenue decreases to $2.5 million

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced second quarter financial results for the period ended June 30, 2011. The Company highlighted significant progress achieved in the second quarter with the continued execution of its turnaround strategy.

8 Aug 2011

Researchers team up to combat age-related macular degeneration

A professor at the University of California, Riverside Bourns College of Engineering has received a $100,000 grant to develop a new technique to fight a disease that gradually destroys vision.

8 Aug 2011

Idera second quarter net loss increases to $6.3 million

Idera Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-Like receptors (TLRs).

5 Aug 2011

Osiris second quarter revenues increase to $10.4 million

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory and cardiovascular disease areas and wound healing, announced today its results for the second quarter ended June 30, 2011.

5 Aug 2011

Novel studies explore new targets to prevent spread of breast cancer

Research into new methods to prevent and slow metastatic breast cancer will be presented this week at the Era of Hope conference, a scientific meeting hosted by the Department of Defense Breast Cancer Research Program.

5 Aug 2011

World RNA Interference market will be worth $4 billion by 2017: New report

By 2017, the world RNA Interference market will be worth $4 billion, according to a new report available from companiesandmarkets.com.

5 Aug 2011

First anti-venom for scorpion bites approved by FDA

The U.S. Food and Drug Administration (FDA) has approved a Mexican-made drug that is the first specific treatment for stings by the most common type of scorpion in the United States. The new preparation called Anascorp is found to have few allergic reactions and was approved after a series of clinical trials by the University of Arizona.

5 Aug 2011

Entomologist to study how immune system responds to rickettsial infection

Summer for most people means time spent outdoors, which could also mean increased exposure to bugs and, possibly, arthropod-borne diseases, such as "rickettsial diseases" - infectious diseases spread by bacteria, which, generally, are transmitted by lice, fleas, ticks and mites.

5 Aug 2011

FDA approves first scorpion antivenom

The U.S. Food and Drug Administration today approved Anascorp-, an antivenom produced in Mexico and tested in clinical trials conducted through the University of Arizona, for use in treating patients suffering the effects of scorpion sting.

5 Aug 2011

PCF funds 10 new Challenge Awards for prostate cancer research

The Prostate Cancer Foundation today announced that it has funded 10 new Challenge Awards for accelerating scientific discovery and new treatments for prostate cancer patients.

5 Aug 2011

Virginia Tech student receives prestigious award for cellular signaling receptor study linked to diabetes, obesity

Stephanie Nicole "Nikki" Lewis, a graduate student in the interdisciplinary doctoral program in genetics, bioinformatics, and computational biology at Virginia Tech, has been awarded the prestigious Ruth L. Kirschstein National Research Service Award for Predoctoral Research through the National Institutes of Health for her study of a cellular signaling receptor that is associated with chronic inflammatory diseases such as diabetes, obesity, and inflammatory bowel disease.

5 Aug 2011